The gastrointestinal tolerability of bisphosphonates

Aging Clinical and Experimental Research

Volumn 13, Issue 5, 2001, Pages 344-346

  Okolicsanyi, L ^a   Dal Bo', N ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bisphosphonates; Bone resorption; Gastrointestinal tolerability; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; VITAMIN; WATER; ZOLEDRONIC ACID;

ABDOMINAL PAIN; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSPEPSIA; EDITORIAL; ESOPHAGITIS; ESOPHAGUS ULCER; FEMALE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEARTBURN; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; NAUSEA; OSTEOLYSIS; OSTEOPOROSIS; RISK BENEFIT ANALYSIS; STOMACH ULCER; TABLET; VOMITING;

EID: 0035664248     PISSN: 03949532     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03351501     Document Type: Editorial

References (23)

1. Multinational, placebo-controlled, randomised trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
2. Bisphosphonates: A review of their pharmacokinetic properties
3. Risedronate: A clinical review
4. Alendronate use among 812 women: Prevalence of gastrointestinal complaints, noncompliance with patient instructions and discontinuation
5. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
6. Alendronate treatment of the post-menopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling
7. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis
8. Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial
9. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
10. Risedronate therapy prevents corticosteroid-induced bone loss
11. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women
12. Multiple ulcerative esophagitis caused by alendronate
13. Alendronate-induced ulcerative esophagitis
14. Esophageal ulceration due to alendronate
15. Improper alendronate administration and case of pill esophagitis
16. A new probable increasing cause of esophageal ulceration: Alendronate
17. Alendronate associated esophagitis: Endoscopic and pathologic features
18. Esophageal irritation due to alendronate sodium tablets
19. Proportion of osteoporotic post-menopausal women at increased risk for upper gastrointestinal adverse events associated with bisphosphonate therapy
20. UK experience with alendronate and esophageal reaction
21. Incidence of gastrointestinal side effects due to alendronate is high in clinical practice
22. Incidence of adverse oesophageal and gastric events in alendronate users
23. Tolerability of risedronate in postmenopausal women intolerant of alendronate